Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

Ibrutinib is an orally administered inhibitor of Bruton tyrosine kinase that antagonizes B-cell receptor, chemokine, and integrin-mediated signaling. In early-phase studies, ibrutinib demonstrated high response rates and prolonged progression-free survival (PFS) in chronic lymphocytic leukemia (CLL)...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Byrd, John C., Furman, Richard R., Coutre, Steven E., Burger, Jan A., Blum, Kristie A., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Shaw, Yun, Bilotti, Elizabeth, Zhou, Cathy, James, Danelle F., O'Brien, Susan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2015
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4400288/
https://ncbi.nlm.nih.gov/pubmed/25700432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-10-606038
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia